Open access · CC-BY
via OpenAlex
Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper
Thomas Lener, Mario Gimona, Ludwig Aigner, Verena Börger, Edit I. Buzás, Giovanni Camussi, Nathalie Chaput, Devasis Chatterjee, Felipe A. Court, Hernando Antonio Del Portillo, Lorraine O’Driscoll, Stefano Fais, Juan Manuel Falcón‐Pérez, Ursula Felderhoff‐Mueser, Lorenzo José Fraile
Journal of Extracellular Vesicles · 2015 · ▲ 1,605 citations
Abstract
Extracellular vesicles (EVs), such as exosomes and microvesicles, are released by different cell types and participate in physiological and pathophysiological processes. EVs mediate intercellular communication as cell-derived extracellular signalling organelles that transmit specific information from their cell of origin to their target cells. As a result of these properties, EVs of defined cell types may serve as novel tools for various therapeutic approaches, including (a) anti-tumour therapy, (b) pathogen vaccination, (c) immune-modulatory and regenerative therapies and (d) drug delivery. The translation of EVs into clinical therapies requires the categorization of EV-based therapeutics in compliance with existing regulatory frameworks. As the classification defines subsequent requirements for manufacturing, quality control and clinical investigation, it is of major importance to define whether EVs are considered the active drug components or primarily serve as drug delivery vehicles. For an effective and particularly safe translation of EV-based therapies into clinical practice, a high level of cooperation between researchers, clinicians and competent authorities is essential. In this position statement, basic and clinical scientists, as members of the International Society for Extracellular Vesicles (ISEV) and of the European Cooperation in Science and Technology (COST) program of the European Union, namely European Network on Microvesicles and Exosomes in Health and Disease (ME-HaD), summarize recent developments and the current knowledge of EV-based therapies. Aspects of safety and regulatory requirements that must be considered for pharmaceutical manufacturing and clinical application are highlighted. Production and quality control processes are discussed. Strategies to promote the therapeutic application of EVs in future clinical studies are addressed.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3402/jev.v4.30087
- Canonical
- link ↗
- Fetched
- 2026-10-03 MST
Cite this
APA
Lener, T., Gimona, M., Aigner, L., Börger, V., Buzás, E.I., Camussi, G., Chaput, N., Chatterjee, D., Court, F.A., Portillo, H.A.D., O’Driscoll, L., Fais, S., Falcón‐Pérez, J.M., Felderhoff‐Mueser, U., Fraile, L.J., Gho, Y.S., Görgens, A., Gupta, R.C., Hendrix, A., & Hermann, D.M. (2015). Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper. <em>Journal of Extracellular Vesicles</em>. https://doi.org/10.3402/jev.v4.30087
Vancouver
Lener T, Gimona M, Aigner L, Börger V, Buzás EI, Camussi G, et al. Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper. Journal of Extracellular Vesicles. 2015. doi:10.3402/jev.v4.30087.
BibTeX
@article{thomas2015Applyi,
title = {Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper},
author = {Thomas Lener and Mario Gimona and Ludwig Aigner and Verena Börger and Edit I. Buzás and Giovanni Camussi and Nathalie Chaput and Devasis Chatterjee and Felipe A. Court and Hernando Antonio Del Portillo and Lorraine O’Driscoll and Stefano Fais and Juan Manuel Falcón‐Pérez and Ursula Felderhoff‐Mueser and Lorenzo José Fraile and Yong Song Gho and André Görgens and Ramesh Chand Gupta and An Hendrix and Dirk Matthias Hermann and Andrew Francis Hill and Fred H. Hochberg and Peter Alexander Horn and Dominique P.V. de Kleijn and Lambros Kordelas},
journal = {Journal of Extracellular Vesicles},
year = {2015},
doi = {10.3402/jev.v4.30087},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Future Pharmacology 2025
Open access · CC-BY
Extracellular Vesicles as Mediators of Intercellular Communication: Implications for Drug Discovery and Targeted Therapies
Circulation Research 2014
Open access · OA
Microvesicles as Cell–Cell Messengers in Cardiovascular Diseases
Preprints.org 2025
Preprint · CC-BY
Extracellular Vesicles as Mediators of Intercellular Communication: Implications for Drug Discovery and Targeted Therapies
International journal of nanomedicine 2026
Open access · OA
Harnessing Natural Extracellular Vesicles to Combat Age-Related Diseases: From Aging Drivers to Therapeutic Opportunities.
International Journal of Veterinary Sciences and Animal Husbandry 2026
Open access · OA
Senotherapeutics: emerging pharmacological strategies for targeting cellular senescence
Circulation Research 2012
Open access · OA